Previous 10 | Next 10 |
home / stock / kymr / kymr articles
INVO (NASDAQ: INVO) and NAYA Biosciences expect to close their previously announced merger in the first quarter of 2024 Experienced, entrepreneu...
IRAK4 oral degrader KT-474 (SAR444656) expected to complete enrollment in both Phase 2 HS and AD studies in fourth quarter of 2024, with topline d...
WATERTOWN, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancin...
BVF PARTNERS L PIL, Board Member at Kymera Therapeutics (NASDAQ:KYMR), reported a large insider buy on November 6, according to a new SEC filing. ...
Although U.S. stocks closed slightly higher on Monday, there were a few notable insider trades. When insiders purchase shares, it indicates their c...
Abstract released today highlights safety, pharmacodynamic and clinical response data collected through July 10, 2023 cut-off Updated data to be p...
WATERTOWN, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancin...
Preclinical models highlight the potential of KT-253 as a monotherapy and combined with the standard of care agent venetoclax for the treatment of...
Gainers Applied UV, Inc. (NASDAQ: AUVI) gained 60.4% to $0.4924. Applied UV said its new product, the Airocide® Pro+ air purification system f...
News, Short Squeeze, Breakout and More Instantly...
Kymera Therapeutics Inc. Company Name:
KYMR Stock Symbol:
NASDAQ Market:
Kymera Therapeutics Inc. Website:
PALM BEACH, Fla., June 20, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Pancreatic cancer is among the most frequently diagnosed and the seventh leading cause of cancer death globally. Pancreatic cancer becomes more common in the Western world. The prevalence rate of panc...
KT-333 demonstrated initial clinical proof of concept across multiple hematological malignancies, including complete responses in two patients with Hodgkin’s lymphoma Robust STAT3 knockdown and positive immunomodulatory effect achieved in blood and tumor KT-333 was well-t...
KT-253 demonstrates initial clinical proof of concept in patients with tumor types shown to be sensitive in preclinical models, including responses in MCC and AML Evidence of target engagement and potent upregulation of p53 pathway biomarkers even at the lowest dose levels in solid tumo...